From Yahoo Finance: 2025-05-21 11:17:00

Aquestive Therapeutics (AQST) is highlighted as a top multibagger stock with a potential 245% upside over the next year. The company specializes in innovative drug delivery systems, such as PharmFilm technology, which offers faster and more reliable medication administration. Aquestive’s FDA-approved treatments, including Libervant and Suboxone, address critical health conditions. Financially, the company reported $11.87 million in Q4 2024 revenue, showing resilience and growth potential. Analysts predict a 12-month average share price of $9.86, reflecting the optimistic outlook on Aquestive’s future in the pharmaceutical industry.



Read more at Yahoo Finance: Analysts See 245% Upside Potential